M7824, a new bifunctional checkpoint inhibitor, targets TGF-β and PD-L1/PD-1 pathways to reduce tumor immune evasion and promote antitumor responses in mouse models of breast and colon cancers. This evidence concerns the gene CD274 and neoplasm.